Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050401 · ClinicalTrials.gov registry record · Phase 3
Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support
A Phase 3 study of Pneumonia, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 10
- Study locations
NCT00050401: Completed Phase 3 study of Pneumonia, sponsored by Pfizer.
NCT00050401 is a Phase 3 study of Pneumonia that has completed, run by Pfizer. The registered enrollment target is 500 participants, below the 4,509-participant average among 47 other Pneumonia trials with a reported enrollment target (89% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050401, a Phase 3 study of Pneumonia, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of the study is to find out if high dose antibiotic (meropenem, MERREM® I.V.), along with another drug called an aminoglycoside (a different type of antibiotic) is effective in decreasing or reducing the rate of antibiotic resistant Pseudomonas aeruginosa, Acinetobacter (germs that can cause pneumonia), and the rate of resistance in other difficult to treat germs which may cause hospital-acquired pneumonia requiring mechanical ventilatory support. The study hopes to show that by increasing the amount of meropenem administered and increasing the duration of infusion (release of the drug into the bloodstream), levels of the drug will stay at target levels in the bloodstream and decrease the ability of difficult to treat germs to resist, or not be killed by, the treatment using this antibiotic (meropenem) or other antibiotics.
Conditions Studied
Interventions
- DRUG MERREM I.V. 2g as a 3 hour infusion every 8 hours
- DRUG vancomycin I.V. 1 g every 12 hours
- DRUG tobramycin I.V. 5 mg/kg every 24 hours
- DRUG MERREM I.V. 1g as a 30 minute infusion every 8 hours
- DRUG MERREM I.V. 500 mg as a 3 hour infusion every 8 hours
Study Locations (10)
New York
- - Albany
- - New York
- - Stony Brook
Arizona
- - Phoenix
Delaware
- - Newark
Indiana
- - Indianapolis
Massachusetts
- - Boston
New Hampshire
- - Lebanon
Ohio
- - Cincinnati
Texas
- - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2002-07 |
| Est. Completion | 2004-09 |
| Phase | Phase 3 |
What the finished NCT00050401 record still lists
NCT00050401 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 4,509-participant average among 47 other Pneumonia trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Pneumonia appearing as the primary indexed condition, and to 5 interventions - of which MERREM I.V. 2g as a 3 hour infusion every 8 hours is the first listed.
NCT00050401 lists 10 locations in 8 states (New York, Arizona, Delaware).
Frequently Asked Questions
What is clinical trial NCT00050401 about?
NCT00050401 is a clinical study titled "Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support". The purpose of the study is to find out if high dose antibiotic (meropenem, MERREM® I.V.), along with another drug called an aminoglycoside (a different type of antibiotic) is effective in decreasing or reducing the rate of antibiotic resistant Pseudomonas aeruginosa, Acinetobacter (germs that can c...
What is the current status of trial NCT00050401?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2002-07. Estimated completion is 2004-09.
What conditions does trial NCT00050401 study?
This clinical trial studies the following conditions: Pneumonia.
What interventions are being tested in trial NCT00050401?
The interventions under investigation include: MERREM I.V. 2g as a 3 hour infusion every 8 hours (DRUG), vancomycin I.V. 1 g every 12 hours (DRUG), tobramycin I.V. 5 mg/kg every 24 hours (DRUG), MERREM I.V. 1g as a 30 minute infusion every 8 hours (DRUG), MERREM I.V. 500 mg as a 3 hour infusion every 8 hours (DRUG).
Who is sponsoring clinical trial NCT00050401?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00050401 being conducted?
This trial has 10 study locations across Arizona, Delaware, Indiana, Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00050401's enrollment target sits among peer trials
500 16th of 47 higher than 32 of 47 other Pneumonia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pneumonia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia
COMPLETED · Phase 3
-
The APS Phenotyping Study
RECRUITING
-
Reducing Overuse of Antibiotics With Decision Support
RECRUITING · NA
-
Extending Dental Care to Nursing Home Residents to Reduce Mouth Infections and Incidence of Pneumonia and Improve Diabetic Glucose Control
RECRUITING · NA
-
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
RECRUITING · NA
-
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia